Three Rivers Pharmaceuticals Obtains Additional Commercial Rights to Infergen from Amgen

19-Sep-2008 - USA

Three Rivers Pharmaceuticals, LLC announced that it has signed a definitive license agreement with Amgen Inc. to expand its commercial rights to the hepatitis C drug Infergen. Three Rivers Pharmaceuticals will obtain commercial rights to Infergen in all markets except Japan. In addition, Three Rivers Pharmaceuticals will obtain commercial rights to China effectiveMarch 31, 2009. Three Rivers Pharmaceuticals currently has commercial rights to Infergen in the United States and Canada.

"The expansion of commercial rights to Infergen compliments Three Rivers Pharmaceuticals strategy to continue to grow its hepatitis C franchise," stated Patrick Kerrish RPh., MBA Three Rivers Pharmaceuticals' Executive Vice President of Business Development.

Infergen, or consensus interferon, is a unique, bio-optimized, selective and highly potent type 1 interferon alpha originally developed by Amgen and launched inthe United Statesin 1997. Infergen is indicated for the treatment of chronic HCV infection in patients 18 years of age or older with compensated liver disease who have anti-HCV serum antibodies and /or the presence of HCV RNA.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances